MedTrace Logo

Clomiphene Citrate for Treatment of Acromegaly

NCT02274311 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-05-07

Study results available
· View outcomes & findings →

Summary

To assess the impact of clomiphene citrate on serum insulin like growth factor 1 and testosterone levels in male acromegalic patients not controlled by surgery, radiotherapy and/or medical treatments (somatostatin analogues, dopamine agonists and/or growth hormone receptor antagonist)

Conditions

Interventions

DRUG

Clomiphene Citrate

Clomiphene citrate, 50 mg, orally for three months

Sponsors & Collaborators

  • Felipe Henning Gaia Duarte

    lead OTHER

Principal Investigators

  • Marcello D Bronstein, MD, PhD · Unit of Neuroendocrinology, Discipline of Endocrinology, Department of Internal Medicine Clinical Hospital of the University of São Paulo Medical School, São Paulo, Brazil

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2014-10-31
Completion
2014-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02274311 on ClinicalTrials.gov